Long Intergenic Non-Protein Coding RNA

Bayer-allied NextRNA Therapeutics winds down operations after missing a milestone in their collaboration

4 weeks ago talkbio0Tagged Bayer, Dana-Farber, Funding, Long Intergenic Non-Protein Coding RNA, Massachusetts biotech, missed milestone, Neoplasms, NextRNA, Plant seeds, Series, shutdowns

NextRNA Therapeutics; Bayer; lncRNA; long non-coding RNA; oncology; biotech wind-down; missed milestone; Massachusetts biotech; seed and Series A funding; Dana-Farber; Carl Novina; 2025 biotech shutdowns

Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI

4 months ago talkbio0Tagged Aortic Valve Insufficiency, Dark color, Eli, Eli Lilly, Genome, Haya, Long Intergenic Non-Protein Coding RNA, Obesity

Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color

Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs

1 year ago talkbio0Tagged Bayer, Drug Development, Long Intergenic Non-Protein Coding RNA, Neoplasms, NextRNA, Partnership

Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development